Balaxi Pharmaceuticals Limited

NSEI:BALAXI Stock Report

Market Cap: ₹3.8b

Balaxi Pharmaceuticals Management

Management criteria checks 3/4

Balaxi Pharmaceuticals' CEO is Ashish Maheshwari, appointed in May 2017, has a tenure of 7.67 years. total yearly compensation is ₹8.25M, comprised of 97% salary and 3% bonuses, including company stock and options. directly owns 1.78% of the company’s shares, worth ₹67.26M. The average tenure of the management team and the board of directors is 5 years and 7.7 years respectively.

Key information

Ashish Maheshwari

Chief executive officer

₹8.3m

Total compensation

CEO salary percentage97.0%
CEO tenure7.7yrs
CEO ownership1.8%
Management average tenure5yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Jan 21
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues

Nov 13
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues

These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Jul 30
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well

Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk

May 29
Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk

Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Feb 10
Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost

Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Feb 09
Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet

Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

Aug 08
Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?

The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

May 20
The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested

A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Feb 03
A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Sep 06
Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively

Jun 03
Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively

Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 12
Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 27
Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?

CEO Compensation Analysis

How has Ashish Maheshwari's remuneration changed compared to Balaxi Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹356m

Jun 30 2024n/an/a

₹454m

Mar 31 2024₹8m₹8m

-₹24m

Dec 31 2023n/an/a

-₹52m

Sep 30 2023n/an/a

-₹106m

Jun 30 2023n/an/a

-₹95m

Mar 31 2023n/an/a

₹460m

Dec 31 2022n/an/a

₹506m

Sep 30 2022n/an/a

₹545m

Jun 30 2022n/an/a

₹511m

Mar 31 2022₹3m₹3m

₹477m

Dec 31 2021n/an/a

₹433m

Sep 30 2021n/an/a

₹421m

Jun 30 2021n/an/a

₹401m

Mar 31 2021₹3m₹3m

₹381m

Dec 31 2020n/an/a

₹312m

Sep 30 2020n/an/a

₹228m

Jun 30 2020n/an/a

₹138m

Mar 31 2020₹3m₹3m

₹61m

Compensation vs Market: Ashish's total compensation ($USD95.30K) is above average for companies of similar size in the Indian market ($USD41.58K).

Compensation vs Earnings: Ashish's compensation has been consistent with company performance over the past year.

CEO

Ashish Maheshwari (54 yo)

7.7yrs

Tenure

₹8,250,000

Compensation

Mr. Ashish Maheshwari has been Managing Director and Executive Director of Balaxi Pharmaceuticals Limited (formerly known as Balaxi Ventures Limited) (formerly known as The Anandam Rubber Company Limited)...

Leadership Team

NamePositionTenureCompensationOwnership
Ashish Maheshwari
MD & Executive Chairman7.7yrs₹8.25m1.78%
₹ 67.3m
Amol Mantri
CFO & Financial Controller5yrsno datano data
Piyush Maheshwari
President Operationsno datano datano data
Mohith Khandelwal
Company Secretary & Compliance Officerless than a yearno datano data
Pranav Maheshwari
Senior Vice President of Business Development5yrsno datano data
Paridhi Maheshwari
Head of Alternate Channels5yrsno datano data
Jignesh Dinesh Shah
Finance Controller of Angolano datano datano data
Pankaj Singh
Head of Operations of Guatemalano datano datano data
Karan Kapoor
Head of Operations of Dominician Republicno datano datano data
Laksh Shewakramani
Compliance Head of Angolano datano datano data
Manish Jumnani
Sales Head of Guatemalano datano datano data
Bharat Jawarani
Sales Head of Dominician Republicno datano datano data

5.0yrs

Average Tenure

Experienced Management: BALAXI's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ashish Maheshwari
MD & Executive Chairman7.7yrs₹8.25m1.78%
₹ 67.3m
Kunal Bhakta
Independent Non-Executive Director7.7yrs₹250.00k2.02%
₹ 76.6m
Akshita Surana
Non-Executive Independent Directorless than a yearno datano data
Minoshi Maheshwari
Non Executive Director7.7yrs₹250.00k1.04%
₹ 39.3m
Gandhi Gamji
Independent Non-Executive Director7.7yrs₹150.00kno data
Mangina Rao
Independent Non-Executive Director4.3yrs₹250.00k0.098%
₹ 3.7m

7.7yrs

Average Tenure

54yo

Average Age

Experienced Board: BALAXI's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 09:48
End of Day Share Price 2025/01/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution